Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck 4Q07

4Q Revenues: $6.2 billion (+3%)

4Q Loss: $1.6 billion (earnings were $473.9 million in 4Q06)

FY Revenues: $24.2 billion (+7%)

FY Earnings: $3.3 billion (-26%)

Comments: 4Q Singulair sales were up 20% to $1.2 billion and FY sales were $4.3 billion (+19%). Global sales of Cozaar and Hyzaar were $891 million in the quarter (+ 3%) and were $3.4 billion for the year (+6%). Worldwide sales of Fosamax and Fosamax plus D were $796 million in the quarter (+1%) and for the year were $3.0 billion (-3%). Fosamax will lose marketing exclusivity in February 2008. Gardasil sales were $339 million for the quarter and $1.5 billion for the year. Sales of the cholesterol drugs Zetia and Vytorin (split between Merck and Schering-Plough) were up 34% in the quarter and FY to $1.5 billion and $5.2 billion, respectively. 4Q loss includes charges related to the U.S. VIOXX Settlement Agreement ($4 billion) and civil governmental investigations, restructuring charges and an insurance arbitration gain. R&D expenses in the quarter were down 20% to $1.4 billion and for the year were $4.9 billion (+2%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters